The Case of Abbokinase and the FDA: The Events Leading to the Suspension of Abbokinase Supplies in the United States-Reference-Cited by-同舟云学术

The Case of Abbokinase and the FDA: The Events Leading to the Suspension of Abbokinase Supplies in the United States

Published:2000-07 Issue:7 Volume:11 Page:841-847
ISSN:1051-0443
Container-title:Journal of Vascular and Interventional Radiology
language:en
Short-container-title:Journal of Vascular and Interventional Radiology

Author:

Hartnell George G.,Gates Julia

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging

Reference13 articles.

1. FDA Important Drug Warning Letter, 1/25/99,1999

2. Urokinase for thrombolysis: when, or will it again be available? Interventional radiologists react to the U.S. FDA policy;Grassi;American Heart Association Cardiovascular Radiology Newsletter,1999

3. Urokinase versus streptokinase in local thrombolysis;van Breda;Radiology,1987

4. Intraarterial fibrinolytic therapy for popliteal and tibial artery obstruction: comparison of streptokinase and urokinase;Traughber;AJR,1987

5. Update on urokinase and streptokinase: a comparison of their efficacy and safety;Bell;Hosp Formul,1988

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review: High temperature short time treatment of cell culture media and feed solutions to mitigate adventitious viral contamination in the biopharmaceutical industry;Biotechnology Progress;2021-01-09

2. Intrapleural Tissue Plasminogen Activator for Traumatic Retained Hemothorax;Annals of Pharmacotherapy;2019-04-21

3. Lytic Therapy for Retained Traumatic Hemothorax;Chest;2019-04

4. Urokinase-An Important Anti-Thromboembolic Drug;Frontiers in Cardiovascular Drug Discovery;2012-03-26

5. Efficacy, Safety, and Cost of Thrombolytic Agents for the Management of Dysfunctional Hemodialysis Catheters: A Systematic Review;Pharmacotherapy;2011-10